EXECUTIVE SUMMARY
Nuclear medicine imaging studies are essential for the diagnosis and management of many diseases, including cancer. The ready availability of medical imaging studies in conjunction with concerns about missed diagnoses has, at times, resulted in inappropriate use and overuse of medical imaging technology, including nuclear imaging. The overuse may have resulted in unnecessary financial burden on the health-care system and in some cases unnecessary exposure to ionizing radiation. Overuse and inconsistent use of imaging procedures prompted a push for multi-stakeholder consensus documents outlining the most appropriate and cost-effective use of advanced medical imaging studies.

Precision medicine is evolving to include a variety of data to optimize patient care and improve outcome. Multimodality imaging is paving the way toward this goal. PET/CT with 18F-FDG is now established as an important imaging modality in many clinical conditions, particularly in oncology. Many tumors demonstrate high glucose metabolism as one of the hallmarks of cancer. PET/CT provides combined anatomic and physiologic (glucose metabolism) information that may be used for initial diagnosis, staging, restaging, treatment response assessment, and prognosis in patients with cancer. Moreover, PET information can contribute significantly when other imaging modalities are equivocal.

AUC INTRODUCTION
The purpose of this document is to describe the appropriate use criteria (AUC) of PET/CT in the treatment response assessment and restaging of patients with cancer. For the purposes of this work, the term assessment of response is taken to mean the period in which the intended target of the therapeutic regimen is being evaluated, whereas the term restaging of disease is taken to mean the period in which there is concern for new or progressive disease after completion of prior therapy. Moreover, this document excludes “initial staging” and “surveillance.”

CLINICAL SCENARIOS FOR LYMPHOMA
Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) are relatively uncommon malignancy that mostly affects young adults. Because of the high cure rate for both HL and NHL, long-term toxicity of available treatments has become an important consideration in the approach to the disease. Accurate staging and assessment of response to treatment have acquired a crucial role to deliver appropriate treatments while minimizing toxicity, particularly for the early and intermediate stages.

PET/CT imaging represents an important tool in the management of HLs and NHLs for initial disease staging and for subsequent response assessment at completion of treatment. HL is invariably FDG-avid and PET is universally accepted as a primary tool for staging and restaging of HL. In NHL, PET imaging should be reserved for tumor subtypes that have a high or at least a moderate degree of FDG uptake, such as diffuse large B-cell lymphomas (DLBCL), follicular lymphomas, most T-cell lymphomas, nodal marginal zone lymphomas, Burkitt’s lymphomas, and mantle cell lymphomas, all of which present FDG avidity.

### Clinical Scenarios for Lymphoma

<table>
<thead>
<tr>
<th>Scenario no.</th>
<th>Description</th>
<th>Appropriateness</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Detection of recurrent disease</td>
<td>Appropriate</td>
<td>8</td>
</tr>
<tr>
<td>2</td>
<td>Treatment response evaluation</td>
<td>Appropriate</td>
<td>9</td>
</tr>
</tbody>
</table>

Rating and Scoring
The scenarios are scored as “appropriate,” “may be appropriate,” or “rarely appropriate” on a scale from 1 to 9. Scores 7–9 indicate that the use of the procedure is appropriate for the specific scenario and is generally considered acceptable. Scores 4–6 indicate that the use of the procedure may be appropriate for the specific scenario. This implies that more research is needed to classify the scenario definitively. Scores 1–3 indicate that the use of the procedure is rarely appropriate for the specific scenario and generally is not considered acceptable.

Methodology
The process for AUC development was modeled after the RAND/UCLA Appropriateness Method for AUC development. It included identifying a list of relevant clinical scenarios, a systematic review of evidence, and a systematic synthesis of available evidence, while adhering to the Institute of Medicine’s standards for developing trustworthy clinical guidance.

This AUC was developed by the Society of Nuclear Medicine and Molecular Imaging with participation from experts affiliated with the following organizations: European Association of Nuclear Medicine; American Society of Clinical Oncology; American College of Nuclear Medicine; Society for Pediatric Radiology; and Canadian Association of Nuclear Medicine.

For the complete manuscript and listing of references, visit: [http://snmmi.files.cms-plus.com/Quality/jnm197988_v1.pdf](http://snmmi.files.cms-plus.com/Quality/jnm197988_v1.pdf)

JNM Reference